


Scalable, Reliable, Domestic Production Processes



Manufacturing Process

Radium-226 (Ra-226) Target Ra-226 Source Material

Ra-226 Reprocessing Recover and Reuse

Reclamation, an integral part of NorthStar's process, helps maintain costs and reduces the reliance on external suppliers for such a scarce isotope



Electron Accelerator Irradiation


Rhodotron® TT300-HE

NorthStar's high-energy electron accelerator (125 kW) can produce up to 200 Ci/yr




Ac-225 Generator Elutions n.c.a. Ac-225 10-Day Half-life

NorthStar's electron accelerator process + generator elutions effectively eliminate Actinium-227 (Ac-227)



Ra-225 Processing Dissolution and Generator Process

Radium-225 (Ra-225) is added to the generator column, where non-carrier-added (n.c.a.) Actinium-225 (Ac-225) grows, in multiple generators and will be used simultaneously



Providing Patients Global Access to Game-Changing Radiopharmaceuticals
www.northstarm.com | 1-844-438-6659



Manufacturing Cornerstones

- n.c.a. Ac-225**
NorthStar's process eliminates Ac-227
- Dedicated Infrastructure**
Commercial scale production capabilities
- Reliable and Scalable**
Electron accelerator + Ra/Ac generator elutions
- Regulatory and Quality Expertise**
Experienced Regulatory and Quality Professionals
- Flexible Ordering and Logistics**
Availability planned to meet commercial needs




Phase I: 30,000 sq ft Ac-225 Production facility
Phase II: 15,000 sq ft planned addition



artt@northstarm.com
For more updates, follow us on **LinkedIn**

Expected to be commercially available in the first half of 2024. NorthStar's Ac-225 is not yet approved by the FDA.



**ADVANCED RADIOPHARMACEUTICAL
AND THERAPEUTIC TECHNOLOGIES**